This clinical trial is focused on studying a condition known as Pure Red Cell Aplasia (PRCA), which can occur after a type of stem cell transplant called allogeneic hematopoietic stem cell transplantation. This condition happens when there is a major mismatch in blood types between the donor and the recipient, leading to a lack of red blood cells. The study is testing a treatment using a medication called isatuximab, which is a type of protein known as a monoclonal antibody. This medication is designed to target and help manage the condition by potentially reducing the time it takes for the body to start producing its own red blood cells again.

The purpose of the study is to evaluate how effective isatuximab is in treating PRCA compared to standard supportive care, which may include treatments like blood transfusions. Participants in the study will receive the medication through an infusion, which means it will be given directly into a vein. The study will follow participants over a period of time to see how quickly they can become independent of transfusions and to monitor any side effects or changes in their quality of life.

Throughout the study, researchers will collect information on various factors, such as the number of blood transfusions needed, levels of certain proteins in the blood, and any side effects experienced. The study aims to provide valuable insights into whether isatuximab can help improve outcomes for patients with PRCA after a stem cell transplant.